Non-contraceptive health benefits of oral contraceptives

References

• Asbell B. The Pill: A biography of the drug that changed the world. Random House, New York 1995
   Google Scholar
• Modugno F, Ness R B, Chen C, et al. Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiol Biomarkers Prev 2005; 14: 2840–7
   PubMed Web of Science ®Google Scholar
• Cramer D W. The relation of endometriosis to menstrual characteristics, smoking and exercise. JAMA 1986; 255: 1904–1908
   PubMed Web of Science ®Google Scholar
• Gilliam M. Acne treatment with a low dose oral contraceptive. Obstet Gynecol 2001; 97(Suppl 1)S9
   Google Scholar
• Thorneycroft I H, Stanczyk F Z, Bradshaw K D, et al. Effect of low dose oral contraceptives on androgenic markers and acne. Contraception 1999; 60: 255–262
   PubMed Web of Science ®Google Scholar
• Kelly R W, Smith S K. Progesterone and anti-progestogens, a comparison of their effect on prostaglandin production by human secretory phase endometrium and decidua. Prostaglandins Leukot Essent Fatty Acids 1987; 29: 181–186
   Web of Science ®Google Scholar
• Kelly R EW, King A E, Critchley H O. Cytokine control in human endometrium. Reproduction 2001; 121: 3–19
   PubMed Web of Science ®Google Scholar
• Killick S R, Bancroft K, Delbaum J. Extending the duration of pill free interval during combined oral contraception. Adv Contracept 1990; 6: 333–340
   Google Scholar
• Wiegratz I, Kuhl H. Long cycle treatment with oral contraceptive. Drugs 2004; 64: 2447–2462
   PubMed Web of Science ®Google Scholar
• Edelman A, Gallo M F, Nichols M D, et al. Continuous vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev Jul 20, 2005, CD004695
   PubMed Web of Science ®Google Scholar
• Nelson A L. Extended-cycle oral contraception: a new option for routine use. Treat Endocrinol 2005; 4: 139–145
   PubMedGoogle Scholar
• Critchley H O, Kelly R W, Brenner R M, et al. Antiprogestin as a model for progesterone withdrawal. Steroids 2003; 68: 1061–1068
   PubMed Web of Science ®Google Scholar
• Kelly R W, King A E, Critchley H O. Inflammatory mediators and endometrial function-focus on perivascular cell. J Reprod Immunol 2002; 57: 81–93
   PubMed Web of Science ®Google Scholar
• Ebert A D, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (Cox-2) inhibitors in endometriosis. New questions old answers?. Eur J Obstet Gynecol Reprod Biol 2005; 122: 144–150
   PubMed Web of Science ®Google Scholar
• Ota H, Igarashi S, Sasaki M, et al. Distribution of cyclooxygenase 2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001; 16: 561–566
   PubMed Web of Science ®Google Scholar
• Ishira H. Gonadotrophin-releasing hormone agonist and danazol normalize aromatase cytochrome p450 expression in eutopic endometrium from women with endometriosis, adenomyosis or leiomyomas. Fertil Steril 2003; 79(Suppl 1)735–742
   PubMedGoogle Scholar
• Attar E. Aromatase and other steroidogenic genes in endometriosis. Translational aspects. Hum Reprod Update 2006; 12: 49–56
   PubMed Web of Science ®Google Scholar
• Noble L S. Prostaglandin E2 stimulates aromatase activity in endometriosis derived stromal cells. J Clin Endocrinol Metab 1997; 82: 600–606
   PubMed Web of Science ®Google Scholar
• Bulum S E, Gurates B, Fang Z, et al. Mechanisms of excessive estrogen formation in endometriosis. J Reprod Immunol 2002; 55: 21–33
   PubMed Web of Science ®Google Scholar
• Maia H, Jr, Casoy J, Correia T, et al. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol 2006; 22: 1–5
   Web of Science ®Google Scholar
• Eskenazi B, Warner M L. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997; 24: 235–258
   PubMed Web of Science ®Google Scholar
• Sutton C JG, Pooley A S, Ewan S P, et al. Follow up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997; 78: 1070–1074
   Google Scholar
• Miller J D, Shaw R D, Casper R F, et al. Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotrophin-releasing hormone agonist. Fertil Steril 1998; 70: 293–296
   PubMed Web of Science ®Google Scholar
• Frontino G, Vercelini P, De Giorgi O, et al. Continuous use of oral contraceptive (OC) for endometriosis associated recurrent dysmenorrhea not responding to cyclic pill regimen. Fertil Steril 2002; 77: S23–S24
   Web of Science ®Google Scholar
• Maia H, Jr, Coelho G, Valente Filho J, et al. Prevention of endometriotic cyst recurrence with continuous oral contraceptives. J Contracept Reprod Health 2004; 9: 152
   Google Scholar
• Sillem M, Schneidereit R, Heithecker R, et al. Use of oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 2003; 8: 162–169
   PubMed Web of Science ®Google Scholar
• Bielgmayer C. Concentration of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995; 9: 307–312
   PubMed Web of Science ®Google Scholar
• Maia H, Jr., Maltez A, Studart E, et al. Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium. Gynecol Endocrinol 2005; 21: 57–61
   PubMed Web of Science ®Google Scholar
• Maia H, Jr., Correa T, Freitas L, et al. Cyclooxygenase-2 expression in the endometrium and its relationship to bleeding in users of continuous oral contraceptives. Gynecol Endocrinol 2006; 22: 96–100
   PubMed Web of Science ®Google Scholar
• Schrager S. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician 2002; 65: 2073–2080
   PubMed Web of Science ®Google Scholar
• Vessey M P, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. Br Med J 1993; 306: 182–186
   PubMed Web of Science ®Google Scholar
• Bergqvist A, Ljungberg O, Myhre E. Human endometrium and endometriotic tissue obtained simultaneously: A comparative histological study. Int J Gynecol Pathol 1984; 3: 135–145
   PubMed Web of Science ®Google Scholar
• Darrow S L, Vena J E, Batt R E, et al. Menstrual cycle characteristics and the risk of endometriosis. Epidemiology 1993; 4: 135–142
   PubMed Web of Science ®Google Scholar
• Andrist L C. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70: 359–363
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Hommel H H, Zimmermann T, Kuhl L. Attitude of German women and gynecologists toward long cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42
   PubMed Web of Science ®Google Scholar
• Michaelson K, Baron J A, Farahmand B Y, et al. Oral contraceptive use and the risk of hip fracture: a case control study. Lancet 1999; 353: 1481–1484
   PubMed Web of Science ®Google Scholar
• Apgar B S. Dysmenorrhea and dysfunctional uterine bleeding. Prim Care 1997; 24: 161–178
   PubMed Web of Science ®Google Scholar
• Larson G, Milsom I, Lindstedt G, et al. The influence of a low dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992; 46: 327–334
   PubMed Web of Science ®Google Scholar
• Smith S K, Abel M H, Kelly R W, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 1981; 88: 434–442
   PubMedGoogle Scholar
• Coll Capdevilla C. Dysfunctional uterine bleeding and dysmenorrhea. Eur J Contracept Reprod Health Care 1997; 2: 229–237
   PubMedGoogle Scholar
• Bonnar J, Sheppard B L. Treatment of menorrhagia during menstruation. Randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. Br Med J 1996; 313: 579–582
   PubMed Web of Science ®Google Scholar
• Maia H, Jr, Maltez A, Coelho G, et al. Insertion of Mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc 2003; 10: 512–516
   PubMedGoogle Scholar
• Frazer I S, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin inhibiting agents in women with a complaint of menorrhagia. Aust NZ J Obstet Gynaecol 1991; 31: 66–70
   PubMed Web of Science ®Google Scholar
• Lyer V, Farquhar C, Jepson R. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2003, CD001016
   Web of Science ®Google Scholar
• Koike H, Egawa W, Ohtsuka T, et al. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 133–137
   PubMed Web of Science ®Google Scholar
• Stewart P J, Zaloudeck C T, Imman M M, et al. Effect of dexamethasone and indomethacin on estrogen induced uterine growth. Life Sci 1983; 33: 2349–2356
   PubMed Web of Science ®Google Scholar
• Cramer S F, Patel D. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435–439
   PubMed Web of Science ®Google Scholar
• Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case control study. Br J Obstet Gynaecol 1999; 106: 857–860
   PubMedGoogle Scholar
• Friedman A J, Thomas P P. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas?. Obstet Gynecol 1995; 85: 631–635
   PubMed Web of Science ®Google Scholar
• Bulun S E, Simpson E R, Word R A. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994; 78: 736–743
   PubMed Web of Science ®Google Scholar
• Maia H, Jr, Pimentel K, Casoy J, et al. Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. Gynecol Endocrinol 2007; 23: 320–324
   PubMed Web of Science ®Google Scholar
• Maia H, Jr, Casoy J, Pimentel K, et al. The effect of oral contraceptives on aromatase expression in the endometrium of myomatous uteri (abstract). Proceedings of the 9th World Congress on Controversies in Obstetrics, Gynecology and Infertility, Barcelona, Spain. 2007; A55
   Google Scholar
• Kailas N A, Sifakis S, Koumantakis E. Contraception during perimenopause. Eur J Contracept Reprod Health Care 2005; 10: 19–25
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami H O, Baron J A, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 277–284
   PubMed Web of Science ®Google Scholar
• Ness R B, Grisso J A, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000; 152: 233–238
   PubMed Web of Science ®Google Scholar
• Gross T P, Schlesselman J J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994; 83: 419–424
   PubMed Web of Science ®Google Scholar
• Speroff L, Darney P. A clinical guide for contraception4th edn. Lippincott Williams & Wilkins, Philadelphia 2005
   Google Scholar